Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. Park JR, et al. Among authors: beiske kh. Cancer. 2022 Nov 1;128(21):3775-3783. doi: 10.1002/cncr.34445. Epub 2022 Sep 13. Cancer. 2022. PMID: 36101004 Free PMC article.
Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group.
Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F. Burchill SA, et al. Cancer. 2017 Apr 1;123(7):1095-1105. doi: 10.1002/cncr.30380. Epub 2016 Dec 16. Cancer. 2017. PMID: 27984660 Free article. Review.
Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.
Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson AD, Matthay KK; International neuroblastoma Risk Group Task Force. Beiske K, et al. Br J Cancer. 2009 May 19;100(10):1627-37. doi: 10.1038/sj.bjc.6605029. Epub 2009 Apr 28. Br J Cancer. 2009. PMID: 19401690 Free PMC article.
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.
Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM. Berbegall AP, et al. Br J Cancer. 2018 May;118(11):1502-1512. doi: 10.1038/s41416-018-0098-6. Epub 2018 May 14. Br J Cancer. 2018. PMID: 29755120 Free PMC article.
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group.
Ambros IM, Tonini GP, Pötschger U, Gross N, Mosseri V, Beiske K, Berbegall AP, Bénard J, Bown N, Caron H, Combaret V, Couturier J, Defferrari R, Delattre O, Jeison M, Kogner P, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Valent A, Van Roy N, Villamon E, Janousek D, Pribill I, Glogova E, Attiyeh EF, Hogarty MD, Monclair TF, Holmes K, Valteau-Couanet D, Castel V, Tweddle DA, Park JR, Cohn S, Ladenstein R, Beck-Popovic M, De Bernardi B, Michon J, Pearson ADJ, Ambros PF. Ambros IM, et al. J Clin Oncol. 2020 Nov 1;38(31):3685-3697. doi: 10.1200/JCO.18.02132. Epub 2020 Sep 9. J Clin Oncol. 2020. PMID: 32903140 Free PMC article.
A multilocus technique for risk evaluation of patients with neuroblastoma.
Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N, Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF. Ambros IM, et al. Clin Cancer Res. 2011 Feb 15;17(4):792-804. doi: 10.1158/1078-0432.CCR-10-0830. Clin Cancer Res. 2011. PMID: 21325297 Free article.
Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee.
Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H. Suganuma R, et al. Pediatr Blood Cancer. 2013 Mar;60(3):363-70. doi: 10.1002/pbc.24238. Epub 2012 Jun 28. Pediatr Blood Cancer. 2013. PMID: 22744966 Free PMC article.
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Bellini A, Pötschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clément N, Combaret V, Font de Mora J, George SL, Jiménez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Mühlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G. Bellini A, et al. J Clin Oncol. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. Epub 2021 Jun 11. J Clin Oncol. 2021. PMID: 34115544 Free PMC article.
Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.
Kohler JA, Rubie H, Castel V, Beiske K, Holmes K, Gambini C, Casale F, Munzer C, Erminio G, Parodi S, Navarro S, Marquez C, Peuchmaur M, Cullinane C, Brock P, Valteau-Couanet D, Garaventa A, Haupt R. Kohler JA, et al. Eur J Cancer. 2013 Nov;49(17):3671-9. doi: 10.1016/j.ejca.2013.07.002. Epub 2013 Jul 29. Eur J Cancer. 2013. PMID: 23907002 Clinical Trial.
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup.
Martinez-Monleon A, Kryh Öberg H, Gaarder J, Berbegall AP, Javanmardi N, Djos A, Ussowicz M, Taschner-Mandl S, Ambros IM, Øra I, Sandstedt B, Beiske K, Ladenstein R, Noguera R, Ambros PF, Gordon Murkes L, Ljungman G, Kogner P, Fransson S, Martinsson T. Martinez-Monleon A, et al. Sci Rep. 2022 Jul 20;12(1):12420. doi: 10.1038/s41598-022-16455-1. Sci Rep. 2022. PMID: 35859155 Free PMC article.
123 results